Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-04

AUTHORS

Kostas Delaunay, Julien Edeline, Yan Rolland, Nicolas Lepareur, Sophie Laffont, Xavier Palard, Christelle Bouvry, Samuel Le Sourd, Marc Pracht, Valérie Ardisson, Nicolas Noiret, Éric Bellissant, Etienne Garin

ABSTRACT

PurposeThis study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.MethodsResults of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism.ResultsThe mean injected activity of 188Re-SSS Lipiodol was 1645 ± 361 MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4 ± 0.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6 h, declining rapidly thereafter. On average, 1.5 ± 1.6% of administered activity was eliminated in urine and feces over 72 h. Overall, 90.7 ± 1.6% of detected activity on SPECT studies was found in the liver (74.9 ± 1.8% in tumours and 19.1 ± 1.7% in the healthy liver) and 9.3 ± 1.6% in the lungs (5.7 ± 1.1% in right and 3.7 ± 0.5% in left lungs). Mean doses absorbed were 7.9 ± 3.7Gy to the whole liver, 42.7 ± 34.0Gy to the tumours, 10.2 ± 3.7Gy to the healthy liver, and 1.5 ± 1.2Gy to the lungs. Four patients had stable disease on CT scans at 2 months. The first patient with rapidly progressive disease died at 1 month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity.Conclusion188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study. More... »

PAGES

1506-1517

References to SciGraph publications

  • 2005-12-07. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2003-12-23. Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9

    DOI

    http://dx.doi.org/10.1007/s00259-019-04277-9

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1111911785

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30715571


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Hepatocellular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Combinations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Embolization, Therapeutic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intra-Arterial", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Iodized Oil", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lung", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organometallic Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiometry", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiopharmaceuticals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tissue Distribution", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, Emission-Computed, Single-Photon", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, X-Ray Computed", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
                "University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Delaunay", 
            "givenName": "Kostas", 
            "id": "sg:person.016057404645.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016057404645.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "University of Rennes 1, Rennes, France", 
                "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
                "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Edeline", 
            "givenName": "Julien", 
            "id": "sg:person.0657306623.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Medical Imaging, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
                "INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rolland", 
            "givenName": "Yan", 
            "id": "sg:person.0641627157.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641627157.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France", 
                "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lepareur", 
            "givenName": "Nicolas", 
            "id": "sg:person.01276035557.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276035557.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Laffont", 
            "givenName": "Sophie", 
            "id": "sg:person.0613252755.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613252755.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
                "University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Palard", 
            "givenName": "Xavier", 
            "id": "sg:person.0704702656.95", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704702656.95"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bouvry", 
            "givenName": "Christelle", 
            "id": "sg:person.011140724323.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011140724323.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Le Sourd", 
            "givenName": "Samuel", 
            "id": "sg:person.01110132160.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110132160.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pracht", 
            "givenName": "Marc", 
            "id": "sg:person.01363611400.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363611400.69"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.417988.b", 
              "name": [
                "Radiopharmacy, Cancer Institute Eug\u00e8ne Marquis, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ardisson", 
            "givenName": "Val\u00e9rie", 
            "id": "sg:person.01071602521.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071602521.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Noiret", 
            "givenName": "Nicolas", 
            "id": "sg:person.0672626707.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672626707.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.411154.4", 
              "name": [
                "University of Rennes 1, Rennes, France", 
                "INSERM CIC 1414 Clinical Investigation Center, Rennes, France", 
                "Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bellissant", 
            "givenName": "\u00c9ric", 
            "id": "sg:person.01115151652.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115151652.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.410368.8", 
              "name": [
                "Department of Nuclear Medicine, Cancer Institute Eug\u00e8ne Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France", 
                "University of Rennes 1, Rennes, France", 
                "INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Garin", 
            "givenName": "Etienne", 
            "id": "sg:person.0620512077.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620512077.06"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00259-005-1954-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050009698", 
              "https://doi.org/10.1007/s00259-005-1954-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-003-1402-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002756691", 
              "https://doi.org/10.1007/s00259-003-1402-z"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-02-04", 
        "datePublishedReg": "2019-02-04", 
        "description": "PurposeThis study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.MethodsResults of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72\u00a0h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism.ResultsThe mean injected activity of 188Re-SSS Lipiodol was 1645\u2009\u00b1\u2009361\u00a0MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4\u2009\u00b1\u20090.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6\u00a0h, declining rapidly thereafter. On average, 1.5\u2009\u00b1\u20091.6% of administered activity was eliminated in urine and feces over 72\u00a0h. Overall, 90.7\u2009\u00b1\u20091.6% of detected activity on SPECT studies was found in the liver (74.9\u2009\u00b1\u20091.8% in tumours and 19.1\u2009\u00b1\u20091.7% in the healthy liver) and 9.3\u2009\u00b1\u20091.6% in the lungs (5.7\u2009\u00b1\u20091.1% in right and 3.7\u2009\u00b1\u20090.5% in left lungs). Mean doses absorbed were 7.9\u2009\u00b1\u20093.7Gy to the whole liver, 42.7\u2009\u00b1\u200934.0Gy to the tumours, 10.2\u2009\u00b1\u20093.7Gy to the healthy liver, and 1.5\u2009\u00b1\u20091.2Gy to the lungs. Four patients had stable disease on CT scans at 2\u00a0months. The first patient with rapidly progressive disease died at 1\u00a0month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity.Conclusion188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00259-019-04277-9", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1297401", 
            "issn": [
              "1619-7070", 
              "1619-7089"
            ], 
            "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "46"
          }
        ], 
        "keywords": [
          "hepatocellular carcinoma patients", 
          "carcinoma patients", 
          "massive tumor progression", 
          "treatment-related toxicity", 
          "favorable biodistribution profile", 
          "stable disease", 
          "progressive disease", 
          "first patient", 
          "liver injection", 
          "mean doses", 
          "clinical trials", 
          "stool samples", 
          "administered activity", 
          "CT scan", 
          "healthy liver", 
          "early death", 
          "patients", 
          "SPECT studies", 
          "injected activity", 
          "PurposeThis study", 
          "tumor progression", 
          "Lipiodol", 
          "whole liver", 
          "serum samples", 
          "MIRD formalism", 
          "phase I", 
          "lung", 
          "liver", 
          "tumors", 
          "uptake ratio", 
          "conservative approach", 
          "biodistribution profile", 
          "radioembolization", 
          "biodistribution", 
          "disease", 
          "doses", 
          "months", 
          "urine", 
          "dosimetry assessment", 
          "vivo stability", 
          "preliminary results", 
          "Evaluation Committee", 
          "study", 
          "blood", 
          "activity", 
          "uptake", 
          "MethodsResults", 
          "progression", 
          "trials", 
          "MBq", 
          "death", 
          "scans", 
          "injection", 
          "organs", 
          "feces", 
          "toxicity", 
          "assessment", 
          "samples", 
          "Committee", 
          "results", 
          "events", 
          "dosimetry", 
          "date", 
          "profile", 
          "quantification", 
          "ratio", 
          "time", 
          "analysis", 
          "compounds", 
          "approach", 
          "determination", 
          "stability", 
          "planar", 
          "formalism", 
          "intra-arterial liver injection", 
          "Phase I Lip-Re 1 study", 
          "I Lip-Re 1 study", 
          "Lip-Re 1 study", 
          "Lipiodol biodistribution", 
          "tomoscintigraphic (SPECT) studies", 
          "non-tumour uptake ratio", 
          "trial independent evaluation committee", 
          "independent evaluation committee", 
          "SSS Lipiodol", 
          "Lipiodol compounds", 
          "Phase 1 Lip-Re I clinical trial", 
          "Lip-Re I clinical trial", 
          "I clinical trial", 
          "Lipiodol radioembolization"
        ], 
        "name": "Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization", 
        "pagination": "1506-1517", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1111911785"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00259-019-04277-9"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30715571"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00259-019-04277-9", 
          "https://app.dimensions.ai/details/publication/pub.1111911785"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:50", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_800.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00259-019-04277-9"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04277-9'


     

    This table displays all metadata directly associated to this object as RDF triples.

    349 TRIPLES      22 PREDICATES      138 URIs      128 LITERALS      28 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00259-019-04277-9 schema:about N00294fb0203c4a2a8968d8d0828ad090
    2 N10638bb7b37a4b9388802cc15cddcb61
    3 N116370c17f2d4d5c9938bb009d27c13d
    4 N239193f9c97348a4bf53533e0c37ed27
    5 N27eec7aecee34742be94192259b70673
    6 N2a970b9eab2041fc89458c2f5a2301fc
    7 N2eb4f1afae2a48259db2a35d0c34436a
    8 N3528001e5c9146ab8db1338edafe7efb
    9 N5972cbe5e7874b2abcc4edbdacda474c
    10 N5e8b715f9fa3456899f379021a339af6
    11 N6fee9cda5e214074a73317b509e8923b
    12 N782931ab22b74f8e85a1874cc07332f3
    13 N8f96dcd495974ce78da564ad6035aaf9
    14 N963bdbef2d0945018f7df8d289935d86
    15 Nbaa2a6e15f694b88aa41f98953f82476
    16 Nbf917c64c02c4574837fe2853b1a25e9
    17 Nc24319afc81d4362b92e1c92e349b1a0
    18 Ne077941bda874519b730d3a231e7d141
    19 Ned3fa4056c7043e0ba31986a03f071a4
    20 Nf8629e11c5be4276a24cbe154069678a
    21 Nfa55d6aef0f149838054db5180dbdce4
    22 anzsrc-for:11
    23 anzsrc-for:1103
    24 schema:author Nc1cbe6408afe4d359b9960d2ae4eade8
    25 schema:citation sg:pub.10.1007/s00259-003-1402-z
    26 sg:pub.10.1007/s00259-005-1954-1
    27 schema:datePublished 2019-02-04
    28 schema:datePublishedReg 2019-02-04
    29 schema:description PurposeThis study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.MethodsResults of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism.ResultsThe mean injected activity of 188Re-SSS Lipiodol was 1645 ± 361 MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4 ± 0.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6 h, declining rapidly thereafter. On average, 1.5 ± 1.6% of administered activity was eliminated in urine and feces over 72 h. Overall, 90.7 ± 1.6% of detected activity on SPECT studies was found in the liver (74.9 ± 1.8% in tumours and 19.1 ± 1.7% in the healthy liver) and 9.3 ± 1.6% in the lungs (5.7 ± 1.1% in right and 3.7 ± 0.5% in left lungs). Mean doses absorbed were 7.9 ± 3.7Gy to the whole liver, 42.7 ± 34.0Gy to the tumours, 10.2 ± 3.7Gy to the healthy liver, and 1.5 ± 1.2Gy to the lungs. Four patients had stable disease on CT scans at 2 months. The first patient with rapidly progressive disease died at 1 month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity.Conclusion188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study.
    30 schema:genre article
    31 schema:inLanguage en
    32 schema:isAccessibleForFree false
    33 schema:isPartOf N57d4bc9554b1413f923a63b024878a74
    34 Nfa8dbd8de4f544e0a185a84a0f28ccbc
    35 sg:journal.1297401
    36 schema:keywords CT scan
    37 Committee
    38 Evaluation Committee
    39 I Lip-Re 1 study
    40 I clinical trial
    41 Lip-Re 1 study
    42 Lip-Re I clinical trial
    43 Lipiodol
    44 Lipiodol biodistribution
    45 Lipiodol compounds
    46 Lipiodol radioembolization
    47 MBq
    48 MIRD formalism
    49 MethodsResults
    50 Phase 1 Lip-Re I clinical trial
    51 Phase I Lip-Re 1 study
    52 PurposeThis study
    53 SPECT studies
    54 SSS Lipiodol
    55 activity
    56 administered activity
    57 analysis
    58 approach
    59 assessment
    60 biodistribution
    61 biodistribution profile
    62 blood
    63 carcinoma patients
    64 clinical trials
    65 compounds
    66 conservative approach
    67 date
    68 death
    69 determination
    70 disease
    71 doses
    72 dosimetry
    73 dosimetry assessment
    74 early death
    75 events
    76 favorable biodistribution profile
    77 feces
    78 first patient
    79 formalism
    80 healthy liver
    81 hepatocellular carcinoma patients
    82 independent evaluation committee
    83 injected activity
    84 injection
    85 intra-arterial liver injection
    86 liver
    87 liver injection
    88 lung
    89 massive tumor progression
    90 mean doses
    91 months
    92 non-tumour uptake ratio
    93 organs
    94 patients
    95 phase I
    96 planar
    97 preliminary results
    98 profile
    99 progression
    100 progressive disease
    101 quantification
    102 radioembolization
    103 ratio
    104 results
    105 samples
    106 scans
    107 serum samples
    108 stability
    109 stable disease
    110 stool samples
    111 study
    112 time
    113 tomoscintigraphic (SPECT) studies
    114 toxicity
    115 treatment-related toxicity
    116 trial independent evaluation committee
    117 trials
    118 tumor progression
    119 tumors
    120 uptake
    121 uptake ratio
    122 urine
    123 vivo stability
    124 whole liver
    125 schema:name Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization
    126 schema:pagination 1506-1517
    127 schema:productId N0ab17c9779b648088e8c45c1bc1fd0bb
    128 Ncd661aff1b9a469eb146abbc18bc1b80
    129 Nf2a95ce1135248f6a8cdb6134806133d
    130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111911785
    131 https://doi.org/10.1007/s00259-019-04277-9
    132 schema:sdDatePublished 2022-01-01T18:50
    133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    134 schema:sdPublisher Nd33d9f6712f2465eb46b3d263257f39d
    135 schema:url https://doi.org/10.1007/s00259-019-04277-9
    136 sgo:license sg:explorer/license/
    137 sgo:sdDataset articles
    138 rdf:type schema:ScholarlyArticle
    139 N00294fb0203c4a2a8968d8d0828ad090 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Embolization, Therapeutic
    141 rdf:type schema:DefinedTerm
    142 N0ab17c9779b648088e8c45c1bc1fd0bb schema:name pubmed_id
    143 schema:value 30715571
    144 rdf:type schema:PropertyValue
    145 N10638bb7b37a4b9388802cc15cddcb61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Disease Progression
    147 rdf:type schema:DefinedTerm
    148 N116370c17f2d4d5c9938bb009d27c13d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Tomography, Emission-Computed, Single-Photon
    150 rdf:type schema:DefinedTerm
    151 N19d38be6297c426995c51a0d3cad4265 rdf:first sg:person.0657306623.46
    152 rdf:rest Ne4b31c3918b949769a73aa27611f045f
    153 N1b32cb17bc524ad2b4a1424e9f281328 rdf:first sg:person.0672626707.15
    154 rdf:rest N95f97fd70b31450db0536f89e9047acc
    155 N239193f9c97348a4bf53533e0c37ed27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Male
    157 rdf:type schema:DefinedTerm
    158 N27eec7aecee34742be94192259b70673 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Humans
    160 rdf:type schema:DefinedTerm
    161 N28c2c89ad3c840b79858e5ea90013985 rdf:first sg:person.0704702656.95
    162 rdf:rest N7be13ccd659745c7b34d6a0dd9cbeeda
    163 N2a970b9eab2041fc89458c2f5a2301fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Iodized Oil
    165 rdf:type schema:DefinedTerm
    166 N2eb4f1afae2a48259db2a35d0c34436a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Carcinoma, Hepatocellular
    168 rdf:type schema:DefinedTerm
    169 N3528001e5c9146ab8db1338edafe7efb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Injections, Intra-Arterial
    171 rdf:type schema:DefinedTerm
    172 N3d21c98a4861436f9f07bce469720927 rdf:first sg:person.01363611400.69
    173 rdf:rest N6f6746db427a44a581a6d883a0e3ab97
    174 N439d43a90120424599ad2ca80f66ef25 rdf:first sg:person.01276035557.58
    175 rdf:rest N62953303a5bc4dc1a36e04b8863d220e
    176 N54f635541fc34a5a935b554bf2ea6ffc rdf:first sg:person.01110132160.38
    177 rdf:rest N3d21c98a4861436f9f07bce469720927
    178 N57d4bc9554b1413f923a63b024878a74 schema:volumeNumber 46
    179 rdf:type schema:PublicationVolume
    180 N5972cbe5e7874b2abcc4edbdacda474c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Middle Aged
    182 rdf:type schema:DefinedTerm
    183 N5e8b715f9fa3456899f379021a339af6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Lung
    185 rdf:type schema:DefinedTerm
    186 N62953303a5bc4dc1a36e04b8863d220e rdf:first sg:person.0613252755.07
    187 rdf:rest N28c2c89ad3c840b79858e5ea90013985
    188 N6f6746db427a44a581a6d883a0e3ab97 rdf:first sg:person.01071602521.66
    189 rdf:rest N1b32cb17bc524ad2b4a1424e9f281328
    190 N6fee9cda5e214074a73317b509e8923b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Radiometry
    192 rdf:type schema:DefinedTerm
    193 N782931ab22b74f8e85a1874cc07332f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Tomography, X-Ray Computed
    195 rdf:type schema:DefinedTerm
    196 N7be13ccd659745c7b34d6a0dd9cbeeda rdf:first sg:person.011140724323.05
    197 rdf:rest N54f635541fc34a5a935b554bf2ea6ffc
    198 N8f96dcd495974ce78da564ad6035aaf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Prospective Studies
    200 rdf:type schema:DefinedTerm
    201 N95f97fd70b31450db0536f89e9047acc rdf:first sg:person.01115151652.22
    202 rdf:rest Ne91648e4d5d844538bd209c2432f27a1
    203 N963bdbef2d0945018f7df8d289935d86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name Drug Combinations
    205 rdf:type schema:DefinedTerm
    206 Nbaa2a6e15f694b88aa41f98953f82476 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    207 schema:name Aged
    208 rdf:type schema:DefinedTerm
    209 Nbf917c64c02c4574837fe2853b1a25e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Liver Neoplasms
    211 rdf:type schema:DefinedTerm
    212 Nc1cbe6408afe4d359b9960d2ae4eade8 rdf:first sg:person.016057404645.17
    213 rdf:rest N19d38be6297c426995c51a0d3cad4265
    214 Nc24319afc81d4362b92e1c92e349b1a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    215 schema:name Female
    216 rdf:type schema:DefinedTerm
    217 Ncd661aff1b9a469eb146abbc18bc1b80 schema:name dimensions_id
    218 schema:value pub.1111911785
    219 rdf:type schema:PropertyValue
    220 Nd33d9f6712f2465eb46b3d263257f39d schema:name Springer Nature - SN SciGraph project
    221 rdf:type schema:Organization
    222 Ne077941bda874519b730d3a231e7d141 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Radiopharmaceuticals
    224 rdf:type schema:DefinedTerm
    225 Ne4b31c3918b949769a73aa27611f045f rdf:first sg:person.0641627157.44
    226 rdf:rest N439d43a90120424599ad2ca80f66ef25
    227 Ne91648e4d5d844538bd209c2432f27a1 rdf:first sg:person.0620512077.06
    228 rdf:rest rdf:nil
    229 Ned3fa4056c7043e0ba31986a03f071a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    230 schema:name Liver
    231 rdf:type schema:DefinedTerm
    232 Nf2a95ce1135248f6a8cdb6134806133d schema:name doi
    233 schema:value 10.1007/s00259-019-04277-9
    234 rdf:type schema:PropertyValue
    235 Nf8629e11c5be4276a24cbe154069678a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    236 schema:name Organometallic Compounds
    237 rdf:type schema:DefinedTerm
    238 Nfa55d6aef0f149838054db5180dbdce4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    239 schema:name Tissue Distribution
    240 rdf:type schema:DefinedTerm
    241 Nfa8dbd8de4f544e0a185a84a0f28ccbc schema:issueNumber 7
    242 rdf:type schema:PublicationIssue
    243 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    244 schema:name Medical and Health Sciences
    245 rdf:type schema:DefinedTerm
    246 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    247 schema:name Clinical Sciences
    248 rdf:type schema:DefinedTerm
    249 sg:journal.1297401 schema:issn 1619-7070
    250 1619-7089
    251 schema:name European Journal of Nuclear Medicine and Molecular Imaging
    252 schema:publisher Springer Nature
    253 rdf:type schema:Periodical
    254 sg:person.01071602521.66 schema:affiliation grid-institutes:grid.417988.b
    255 schema:familyName Ardisson
    256 schema:givenName Valérie
    257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071602521.66
    258 rdf:type schema:Person
    259 sg:person.01110132160.38 schema:affiliation grid-institutes:grid.417988.b
    260 schema:familyName Le Sourd
    261 schema:givenName Samuel
    262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110132160.38
    263 rdf:type schema:Person
    264 sg:person.011140724323.05 schema:affiliation grid-institutes:grid.417988.b
    265 schema:familyName Bouvry
    266 schema:givenName Christelle
    267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011140724323.05
    268 rdf:type schema:Person
    269 sg:person.01115151652.22 schema:affiliation grid-institutes:grid.411154.4
    270 schema:familyName Bellissant
    271 schema:givenName Éric
    272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115151652.22
    273 rdf:type schema:Person
    274 sg:person.01276035557.58 schema:affiliation grid-institutes:grid.417988.b
    275 schema:familyName Lepareur
    276 schema:givenName Nicolas
    277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276035557.58
    278 rdf:type schema:Person
    279 sg:person.01363611400.69 schema:affiliation grid-institutes:grid.417988.b
    280 schema:familyName Pracht
    281 schema:givenName Marc
    282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363611400.69
    283 rdf:type schema:Person
    284 sg:person.016057404645.17 schema:affiliation grid-institutes:grid.410368.8
    285 schema:familyName Delaunay
    286 schema:givenName Kostas
    287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016057404645.17
    288 rdf:type schema:Person
    289 sg:person.0613252755.07 schema:affiliation grid-institutes:grid.417988.b
    290 schema:familyName Laffont
    291 schema:givenName Sophie
    292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613252755.07
    293 rdf:type schema:Person
    294 sg:person.0620512077.06 schema:affiliation grid-institutes:grid.410368.8
    295 schema:familyName Garin
    296 schema:givenName Etienne
    297 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620512077.06
    298 rdf:type schema:Person
    299 sg:person.0641627157.44 schema:affiliation grid-institutes:grid.410368.8
    300 schema:familyName Rolland
    301 schema:givenName Yan
    302 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641627157.44
    303 rdf:type schema:Person
    304 sg:person.0657306623.46 schema:affiliation grid-institutes:grid.410368.8
    305 schema:familyName Edeline
    306 schema:givenName Julien
    307 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46
    308 rdf:type schema:Person
    309 sg:person.0672626707.15 schema:affiliation grid-institutes:grid.410368.8
    310 schema:familyName Noiret
    311 schema:givenName Nicolas
    312 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672626707.15
    313 rdf:type schema:Person
    314 sg:person.0704702656.95 schema:affiliation grid-institutes:grid.410368.8
    315 schema:familyName Palard
    316 schema:givenName Xavier
    317 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704702656.95
    318 rdf:type schema:Person
    319 sg:pub.10.1007/s00259-003-1402-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1002756691
    320 https://doi.org/10.1007/s00259-003-1402-z
    321 rdf:type schema:CreativeWork
    322 sg:pub.10.1007/s00259-005-1954-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050009698
    323 https://doi.org/10.1007/s00259-005-1954-1
    324 rdf:type schema:CreativeWork
    325 grid-institutes:grid.410368.8 schema:alternateName ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France
    326 INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France
    327 INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France
    328 University of Rennes 1, Rennes, France
    329 schema:name Department of Medical Imaging, Cancer Institute Eugène Marquis, Rennes, France
    330 Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
    331 Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France
    332 ENSCR, CNRS, ISCR [(Institut des Sciences Chimiques de Rennes)] - UMR 6226, University of Rennes, F-35000, Rennes, France
    333 INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France
    334 INSERM UMR 1099 LTSI, University of Rennes 1, Rennes, France
    335 University of Rennes 1, Rennes, France
    336 rdf:type schema:Organization
    337 grid-institutes:grid.411154.4 schema:alternateName Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France
    338 schema:name Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-epidemiology and Drug Information Center, Rennes University Hospital, Rennes, France
    339 INSERM CIC 1414 Clinical Investigation Center, Rennes, France
    340 University of Rennes 1, Rennes, France
    341 rdf:type schema:Organization
    342 grid-institutes:grid.417988.b schema:alternateName Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
    343 Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France
    344 Radiopharmacy, Cancer Institute Eugène Marquis, Rennes, France
    345 schema:name Department of Medical Oncology, Cancer Institute Eugène Marquis, Rennes, France
    346 Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France
    347 INSERM INRA UMR 1241 NuMeCan, University of Rennes 1, Rennes, France
    348 Radiopharmacy, Cancer Institute Eugène Marquis, Rennes, France
    349 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...